amifostine anhydrous has been researched along with Chronic Disease in 4 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adults with head-and-neck cancer who underwent once-daily RT for 5-7 weeks (total dose, 50-70 Gy) received either open-label amifostine (200 mg/m2 i." | 2.71 | Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Sauer, R; Strnad, V; Wasserman, TH, 2005) |
| "Patients with well-differentiated thyroid cancer have a good prognosis but a significant chance for local recurrence." | 1.32 | Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. ( Elkins, D; Goffman, TE; Karakla, D; Mason, ME; Mendoza, A; Shaffer, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cosar, R | 1 |
| Yurut-Caloglu, V | 1 |
| Eskiocak, S | 1 |
| Ozen, A | 1 |
| Altaner, S | 1 |
| Ibis, K | 1 |
| Turan, N | 1 |
| Denizli, B | 1 |
| Uzal, C | 1 |
| Saynak, M | 1 |
| Parlar, S | 1 |
| Caloglu, M | 1 |
| Uregen, B | 1 |
| Kocak, Z | 1 |
| Mendoza, A | 1 |
| Shaffer, B | 1 |
| Karakla, D | 1 |
| Mason, ME | 1 |
| Elkins, D | 1 |
| Goffman, TE | 1 |
| Wasserman, TH | 1 |
| Brizel, DM | 2 |
| Henke, M | 1 |
| Monnier, A | 1 |
| Eschwege, F | 1 |
| Sauer, R | 1 |
| Strnad, V | 1 |
| Vujaskovic, Z | 1 |
| Thrasher, BA | 1 |
| Jackson, IL | 1 |
| Brizel, MB | 1 |
1 trial available for amifostine anhydrous and Chronic Disease
| Article | Year |
|---|---|
Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Chronic Disease; Female; Follow-Up Studies; Head and Ne | 2005 |
3 other studies available for amifostine anhydrous and Chronic Disease
| Article | Year |
|---|---|
Radiation-induced chronic oxidative renal damage can be reduced by amifostine.
Topics: Amifostine; Animals; Antioxidants; Catalase; Chronic Disease; Cobalt Radioisotopes; Female; Glutathi | 2012 |
Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Chronic Disease; Fatigue; Fem | 2004 |
Radioprotective effects of amifostine on acute and chronic esophageal injury in rodents.
Topics: Acute Disease; Amifostine; Animals; Antigens, Neoplasm; Body Weight; Chronic Disease; Drug Evaluatio | 2007 |